Natera Inc (NTRA)

Industry Diagnostics & Research

This stock can be held in an Investment ISA and an Investment Account

Sell

$226.88

Buy

$232.58

arrow-up$0.90 (+0.39%)

Prices updated at 13 Dec 2025, 00:56 EST

Prices minimum 15 mins delay

Prices in USD

Natera Inc is a provider of diagnostic services predominantly in the United States. It offers various tests which detect chromosomal abnormalities, reasons for miscarriages and paternity.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Diagnostics & Research

Chairman

Dr. Matthew Rabinowitz

CEO

Mr. Steven Leonard Chapman

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

4,434

Head office

13011 McCallen Pass

Austin

United States

78753

+1 650 980-9190

mbrophy@natera.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Dr. Monica Bertagnolli, M.D. Independent Director	-
Mr. Herm Rosenman Independent Director	0.09m
Dr. James I. Healy, M.D.,PhD Independent Director	0.08m
Ms. Ruth W. Brinkley Independent Director	-
Mr. Roelof Frederik Botha Lead Independent Director	0.10m
Dr. Matthew Rabinowitz Executive Chairman of the Board	0.40m
Mr. Jonathan Sheena Director	-
Dr. Roy D. Baynes, M.D.,PhD Independent Director	0.06m
Mr. Michael Brophy Chief Financial Officer and Principal Accounting Officer	0.49m
Dr. Gail B. Marcus Independent Director	0.08m
Mr. Steven Leonard Chapman Director, Chief Executive Officer and President	0.80m
Dr. Rowan E. Chapman, PhD Independent Director	0.09m
Mr. Daniel Rabinowitz Secretary and Chief Legal Officer	-
Mr. Solomon Moshkevich President, Clinical Diagnostics	0.49m
Mr. John Fesko Co-President and Chief Business Officer	0.49m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
JPMorgan Chase & Co	23,257,828
Vanguard Group Inc	12,676,653
T. Rowe Price Associates, Inc.	11,947,415
BlackRock Inc	10,964,351
J.P. Morgan Investment Management, Inc.	7,711,237

Director dealings

Date chevron-l-regular chevron-r-regular	Action
20 Dec 2024	-
23 Dec 2024	-
23 Dec 2024	-
23 Dec 2024	-
20 Dec 2024	-
23 Dec 2024	-
23 Dec 2024	-
20 Dec 2024	-
23 Dec 2024	-
19 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
18 Dec 2024	-
13 Dec 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.